Abstract
Aim In people with type 2 diabetes (T2D) requiring intensification beyond glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and oral antihyperglyc......
小提示:本篇文献需要登录阅读全文,点击跳转登录